IMMP Immutep

Immutep to Present at Investor Conferences

Immutep to Present at Investor Conferences

SYDNEY, AUSTRALIA, May 20, 2022 (GLOBE NEWSWIRE) --   (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announces Immutep has been invited to present at investor conferences, as outlined below.

Wilsons Rapid Insights – 26 May 2022

Presenter: Marc Voigt, CEO and Deanne Miller, COO of Immutep

Presentation time & date: All day on 26 May

Format: In-person conference, 45-minute small group briefings with Q&A

Venue: Four Seasons Hotel Sydney, 199 George St, The Rocks, Sydney NSW 2000 Australia

Information: Institutional investors should contact Wilsons Corporate Access: or visit:

Jefferies Australia MedTech/Biotech Summit – 26 & 27 May 2022

Presenter: Marc Voigt, CEO of Immutep

Presentation time & date: 9.00am AEST on Friday 27 May

Format: This conference will be a virtual format

Information: Please contact your Jefferies representative to register. For questions, please email

Jefferies Global Healthcare Conference – 8 to 10 June 2022

Presenter: Marc Voigt, CEO of Immutep

Presentation time & date: 8:30 AM ET on 10 June

Format: In-person conference, with one to one investor meetings available

Venue: in New York City on June 8-10, 2022

Information: For questions, please email

                     A live webcast and replay of the presentation will be made available at

                     

                     and on the Company’s website following the event.

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS

+61 (0)406 759 268;

U.S. Media:

Tim McCarthy, LifeSci Advisors

+1 (212) 915.2564; 

 



EN
20/05/2022

Underlying

IMMPImmutep

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immutep

 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase...

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's targeted enrolment Futility analysis and completion of patient enrolment remain on track for the first quarter and the third quarter of CY2026, respectively SYDNEY, AUSTRALIA, Feb. 06, 2026 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces...

February 6, 2026 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Quarterly Activities Report Q2 FY26

Immutep Quarterly Activities Report Q2 FY26 Media Release Entered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater ChinaIn January 2026, Immutep received ~A$30 million upfront payment from Dr. Reddy’s and is eligible to receive up to ~A$528 million in potential milestones, plus royalties on commercial sales of eftiStrong operational progress reported for TACTI-004 (KEYNOTE-F91) Phase III trial evaluating efti in first line non-small cell lung cancer (1L NSCLC), with completion o...

January 29, 2026 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Ag...

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levelsDose dependent immunosuppressive effect against a strong foreign antigen observed with continued favourable safety profileSubstantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseasesGiven encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026 including present...

December 22, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Announces Strong Operational Progress in Global TACTI-004 (KEY...

Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolmentStrong operational progress continues globally with over 120 activated clinical sites and 27 countries having received full regulatory approvals including the United States Futility analysis remains on track for the first quarter of CY2026 and completion of patient enrolment in the third quarter of CY2026 SYDNEY, AUSTRALIA, Dec. 16, 2025 (GLOBE ...

December 16, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commer...

Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa Dr. Reddy’s receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront payment of USD 20 million (~AUD 30.2 million) and is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales Sydney, Australia/Hyd...

December 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch